Practice-based Learning & Improvement

Maternal Sepsis, Part 3: Screening

Sepsis is the third leading cause of pregnancy-related death accounting for 23% of maternal deaths in the United States. To promote early recognition and rapid treatment, multiple professional organizations have provided screening and diagnostic criteria, and treatment recommendations. This series…

Maternal Sepsis, Part 2: Definitions, Risk Factors, & Characteristics

Sepsis is the third leading cause of pregnancy-related death accounting for 23% of maternal deaths in the United States. To promote early recognition and rapid treatment, multiple professional organizations have provided screening and diagnostic criteria, and treatment recommendations. This series…

Maternal Sepsis, Part 1: Introduction/Overview

Sepsis is the third leading cause of pregnancy-related death accounting for 23% of maternal deaths in the United States. To promote early recognition and rapid treatment, multiple professional organizations have provided screening and diagnostic criteria, and treatment recommendations. This series…

TOLAC Risk Issues

TOLAC is defined as a trial of labor after one or more cesarean deliveries intended to result in a vaginal birth instead of a scheduled repeat Cesarean Section. Successful vaginal birth after Cesarean (VBAC) rates in TOLAC patients are reported…

Labor Induction-Module 7: Oxytocin Safe Administration

In the US, “Mega” (> $10M) and “Nuclear” (> $100M) closed obstetric claims increased 84% in the last decade; obstetric care is a significant factor. Medications used for cervical ripening or labor induction can cause adverse outcomes when used inappropriately…

Labor Induction-Module 6: Oxytocin Pharmacodynamics

In the US, “Mega” (> $10M) and “Nuclear” (> $100M) closed obstetric claims increased 84% in the last decade; obstetric care is a significant factor. Medications used for cervical ripening or labor induction can cause adverse outcomes when used inappropriately…

Labor Induction-Module 5: Misoprostol

In the US, “Mega” (> $10M) and “Nuclear” (> $100M) closed obstetric claims increased 84% in the last decade; obstetric care is a significant factor. Medications used for cervical ripening or labor induction can cause adverse outcomes when used inappropriately…

Labor Induction-Module 4: Mechanical Methods

In the US, “Mega” (> $10M) and “Nuclear” (> $100M) closed obstetric claims increased 84% in the last decade; obstetric care is a significant factor. Medications used for cervical ripening or labor induction can cause adverse outcomes when used inappropriately…

Labor Induction-Module 3: Cervical Ripening

In the US, “Mega” (> $10M) and “Nuclear” (> $100M) closed obstetric claims increased 84% in the last decade; obstetric care is a significant factor. Medications used for cervical ripening or labor induction can cause adverse outcomes when used inappropriately…

Labor Induction-Module 2: Indications, Contraindications, ARRIVE Trial

In the US, “Mega” (> $10M) and “Nuclear” (> $100M) closed obstetric claims increased 84% in the last decade; obstetric care is a significant factor. Medications used for cervical ripening or labor induction can cause adverse outcomes when used inappropriately…